FLT3 Agonists and Secondary Hematopoietic Malignancies: A Potential Class Effect

Henry W Raeder; Michael W Drazer

doi:10.1158/1078-0432.CCR-24-0460

FLT3 Agonists and Secondary Hematopoietic Malignancies: A Potential Class Effect

Clin Cancer Res. 2024 Jul 15;30(14):2857-2859. doi: 10.1158/1078-0432.CCR-24-0460.

Authors

Henry W Raeder¹, Michael W Drazer^{2

3}

Affiliations

¹ Department of Human Genetics, University of Chicago, Chicago, Illinois.
² Hematology and Oncology, Department of Medicine, University of Chicago, Chicago, Illinois.
³ Genetic Medicine, Department of Medicine, University of Chicago, Chicago, Illinois.

PMID: 38652676
DOI: 10.1158/1078-0432.CCR-24-0460

Abstract

Expansion of conventional dendritic cells via FMS-like tyrosine kinase 3 agonism has promising therapeutic potential in the treatment of advanced solid tumors. In this study, we discuss the results of a clinical trial using GS-3583, an FMS-like tyrosine kinase 3 agonist, that was stopped after a patient in the study developed acute myeloid leukemia. See related article by Tolcher et al., p. 2954.

MeSH terms

Dendritic Cells / drug effects
Dendritic Cells / immunology
Hematologic Neoplasms* / drug therapy
Hematologic Neoplasms* / pathology
Humans
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Myeloid, Acute* / pathology
Neoplasms, Second Primary / drug therapy
fms-Like Tyrosine Kinase 3* / antagonists & inhibitors

Substances

fms-Like Tyrosine Kinase 3
FLT3 protein, human